SCHEMBL8106312

SCHEMBL8106312

CCOC(=O)CCn1c(=O)[nH]c2cccc(Br)c21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 3/20 0.44
LMNA P02545 2/20 0.43
HSD17B10 Q99714 3/20 0.41
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 2/20 0.40
MAPK10 P53779 1/20 0.40
TNF P01375 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
DAO P14920 1/20 0.39
GRIK1 P39086 1/20 0.38
GRIK2 Q13002 1/20 0.38
GRIK3 Q13003 1/20 0.38
GRIK4 Q16099 1/20 0.38
GRIK5 Q16478 1/20 0.38
ADORA3 P0DMS8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3748048 0.93 HSD17B10 (0.47) ALDH1A1KDM4EHSD17B10MAPTSMN1; SMN2
SCHEMBL2311046 0.88 DAO (0.50) ALDH1A1KDM4ELMNAHSD17B10MAPT
SCHEMBL13129781 0.80 KMT2A (0.57) ALDH1A1KDM4ELMNAHSD17B10MAPT
SCHEMBL3754859 0.79 HSD17B10 (0.47) ALDH1A1KDM4EHSD17B10MAPTSMN1; SMN2
SCHEMBL7648358 0.78 KDM4E (0.67) ALDH1A1KDM4EHSD17B10MAPTSMN1; SMN2
SCHEMBL24608420 0.77 CYP1A2 (0.56) ALDH1A1KDM4ELMNAMAPTSMN1; SMN2
SCHEMBL31701365 0.77 RAB9A (0.43) ALDH1A1KDM4EHSD17B10MAPTSMN1; SMN2
SCHEMBL12431694 0.76 DAO (0.51) ALDH1A1KDM4ELMNAHSD17B10MAPT
SCHEMBL3722289 0.76 HSD17B10 (0.45) ALDH1A1KDM4ELMNAHSD17B10MAPT
SCHEMBL10830938 0.72 TNF (0.58) ALDH1A1KDM4ELMNAHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150556-B2 Benzimidazolone chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-06 US disclosed
US-9150556-B2 Benzimidazolone chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-10-06 US disclosed
US-20100240702-A1 Benzimidazolone Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240702-A1 Benzimidazolone Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
WO-2008147697-A1 BENZIMIDAZOLONE CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240702-A1 Benzimidazolone Chymase Inhibitors CMA1, SERPINB1, CPA3 ALDH1A1 2332/4885KDM4E 3615/4885LMNA 1750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.